Printer Friendly Version 

Investor Relations Home

Webcast ImageWebcast
Leerink Rare Disease Roundtable (Live)
10/01/14 at 8:00 a.m. ET
Leerink Rare Disease Roundtable
Wednesday, October 1, 2014 8:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast
ISIS-SMNRx Program Update (Live)
10/10/14 at 11:30 a.m. ET
ISIS-SMNRx Program Update
Friday, October 10, 2014 11:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
ISIS (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$38.83
Change (%) Stock is Down 1.35 (3.36%)
Volume1,931,071
Data as of 09/30/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Featured Report
2013 Interactive Annual Report

Recent Press ReleasesMore >>
DateTitle 
09/24/14Isis Pharmaceuticals to Present at the Leerink Partners Rare Disease Roundtable
CARLSBAD, Calif., Sept. 24, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Leerink Partners Rare Disease Roundtable on Wednesday, October 1, 2014 at 8:00 a.m. ET in New York, NY. A live webcast of the presentation will be available on the "Investors & Media" section of the Company's website, www.isispharm.com.  A replay will be available on the Isis website withi... 
Printer Friendly Version
09/17/14Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin
CARLSBAD, Calif., Sept. 17, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced that it has earned a $4 million milestone payment from Achaogen, Inc. (NASDAQ: AKAO) associated with the initiation of a Phase 3 study of plazomicin in patients with serious multi-drug resistant (MDR), gram-negative bacterial infections.  The Phase 3 study is designed as a superiority study to evaluate the efficacy and safety of plazomicin compared to colistin in patients with bloodstream infecti... 
Printer Friendly Version
09/03/14Isis Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference
CARLSBAD, Calif., Sept. 3, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Morgan Stanley Global Healthcare Conference on Monday, September 8, 2014 at 12:50 p.m. ET in New York, NY. A live webcast of the presentation will be available on the "Investors & Media" section of the Company's website, www.isispharm.com.  A replay will be available on the Isis website wit... 
Printer Friendly Version
09/02/14Drugs from Isis' Lipid Franchise Highlighted at European Society of Cardiology Congress 2014
KYNAMRO®, ISIS-APOCIIIRX AND ISIS-APO(A)RX DATA PRESENTED CARLSBAD, Calif., Sept. 2, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that data from three drugs in its lipid franchise were highlighted in four presentations at the 2014 European Society of Cardiology (ESC) Congress in Barcelona Spain. Isis has created a lipid franchise of antisense drugs designed to provide effective and safe therapeutic options to treat patients with lipid disorders.  This franchi... 
Printer Friendly Version
Upcoming EventsMore >>
DateTitle
10/01/14 8:00 a.m. ET
Leerink Rare Disease Roundtable
10/07/14
through
10/11/14
19th International WMS Congress
LocationBerlinDE
10/10/14 11:30 a.m. ET
ISIS-SMNRx Program Update
10/12/14
through
10/15/14
10th Annual Meeting of the Oligonucleotide Therapeutics Society
LocationSan Diego, CA
10/18/14
through
10/22/14
ASHG 2014
LocationSan Diego, CA
Primary IR Contact
D. Wade Walke, Ph.D.
Vice President, Corporate Communications and Investor Relations
Isis Pharmaceuticals, Inc.
2855 Gazelle Court
Carlsbad, CA 92010
Phone: 760-603-2331

For more information requests, please visit our Information Request page.

If you are interested in Isis Pharmaceuticals’ investment details,
please visit our Investor FAQ page.


Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Online Investor Kit

Quickly download files right from our Investor Relations Web site.

Learn More

Financial Tearsheet

Download a brief overview of Isis.

Learn More

News Feeds

Get the latest.

Subscribe

Receive Isis alerts in your email.

Sign Up